TRAF2 and mantle cell lymphoma: In line with these observations, two of five patient-derived lymphoma xenografts used in our recent study on experimental therapy of MCL with the combination of venetoclax and MCL1 inhibitor S63845 harbored mutations of TRAF2, and both these PDX models were resistant to experimental therapy with ibrutinib (unpublished data) [42].